You can feel confident that TAVR is an established treatment for symptomatic severe aortic stenosis1

TAVR is an established treatment option, with more than 1,000,000 transcatheter aortic valves implanted.2-4

TAVR with the Edwards SAPIEN 3 valve is shown to be safe and reproducible in intermediate risk patients in real world settings5

Events at 30 days S3i
All-cause Mortality 0.9% 0.9% 0.8%
All Stroke 2.0% 2.3% 2.2%
New Pacemaker 11.1% 12.0%* 10.2%*
Major Vascular Complications 6.9% 5.8%* 4.0%*
Length-of-Stay Median (IQR) 3.0%
[2.0%, 4.0%]
[2.0%, 3.0%]
[2.0%, 3.0%]
PVL (Mod/Sev) 4.6% 4.3%* 1.3%*

* Site reported and unadjudicated.

Guide your patients to TAVR treatment with confidence

References:   1. Messenger JC. Trends in United States TAVR practice. Cardiac Interventions Today website. Published April 2018. Accessed February 7, 2019. 2. FDA Letter: SAPIEN approval letter 2011. 3. Mack MJ, Leon MB, Thourani VH. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705. 4. Fifteen Years of TAVR; Where Are They Now? American College of Cardiology, July 20, 2017. 5. Tuzcu E. Real world outcomes of TAVR with the SAPIEN 3 valve in intermediate risk patients: comparison of data from the TVT registry with PARTNER S3 studies. Oral presentation at: EuroPCR 2018; May 2018; Paris, France.